Abstract:Currently, hepatocellular carcinoma (HCC) is the third most common cause of cancer death worldwide; 82% of the cases occur in developing countries, with 55% occurring in China [1]. Liver transplantation (LT), a potentially curative thera peutic modality of HCC, allows radical extirpation of the cancer and restores normal liver function. There is increasing evidence that, in the long term, LT will be the best therapeutic option for cirrhosis-associated HCC [2]. Unfortunately, the recurrence rate is high in HCC patients who undergo LT, which markedly reduces the longterm and medium-term survival of HCC patients [3]. Therefore, risk estimation of post-transplant tumor recurrence is an essential element in selecting a subset of HCC patients for LT. In clinical practice, this risk estimation is based on the number and size of the nodules, and microscopic/macroscopic vascular invasion; and selection criteria for LT have been established to select HCC patients according to these clinical features. The Milan criteria proposed by Mazzaferro and his colleagues – a single lesion of 5 cm or smaller in diameter, or three lesions each smaller than 3 cm in diameter, and without macroscopic vascular invasion – have been accepted worldwide for identifying candidates with good prognosis and low recurrence rates [4]. The Milan criteria were chosen in an attempt to minimize the difference in outcomes between transplanted HCC patients and those who did not have HCC, and these criteria have been adopted for organ allocation in the USA and in Europe [5,6]. Despite their proven utility, many recent data have suggested that these criteria are too restrictive, and many patients with tumor burdens outside the Milan criteria may potentially benefit from LT. Moreover, limiting LT to HCC patients within the Milan criteria may be unjust for those outside of the criteria who could have a favorable outcome with LT. Several expansions of the Milan criteria have been proposed. Yao and coworkers at the University of California, San Francisco (UCSF; CA, USA) reported that LT candidates with a solitary tumor of 6.5 cm in diameter or smaller, or three or fewer nodules with the largest lesion no larger than 4.5 cm in diameter, and a total tumor diameter no larger than 8 cm (the so-called UCSF criteria) achieved excellent results following LT that were not different from those for HCC patients within the Milan criteria [7]. Although the UCSF criteria have been validated by several groups [8], these criteria have not been accepted unanimously, which may be related to the results of a large multi center study that suggested the UCSF criteria to be associated with a 5-year survival rate of less than 50% when applied to preoperative evaluation [9]. In addition, the UCSF criteria allow LT for large tumors, which have been proven to be associated with post-transplant metastatic recurrence [10]. Lastly, both the Milan and the UCSF criteria exclude those patients with more than three nodules, who may obtain good outcomes if the tumors are of a reasonable size. Toso and his colleagues proposed an expansion of the current allocation criteria Zhi Dai, PhD Liver Cancer Institute, Shanghai 200032, PR China dai.zhi@zs-hospital.sh.cn

[Dysplastic Nodule of Liver Versus Early Hepatocellular Carcinoma: a Clinicopathologic and Prognostic Study].

Daily Decrease of Post-Operative Alpha-Fetoprotein by 9% Discriminates Prognosis of HCC: A Multicenter Retrospective Study.

Prognostic Significance of Preoperative Serum Alpha- Fetoprotein in Hepatocellular Carcinoma and Correlation with Clinicopathological Factors: a Single-center Experience from China.

Stromal morphological changes and immunophenotypic features of precancerous lesions and hepatocellular carcinoma

Distinguished Prognosis of Hepatocellular Carcinoma with or Without Cirrhosis: A Long-term Follow-up Analysis

Pathological Characteristics, Pcna Labeling Index and Dna Index in Prognostic Evaluation of Patients with Moderately Differentiated Hepatocellular Carcinoma

Prognostic Performance of the China Liver Cancer Staging System in Hepatocellular Carcinoma Following Transarterial Chemoembolization.

A novel panel of biomarkers in distinction of small well-differentiated HCC from dysplastic nodules and outcome values

Clinicopathological Features and Prognostic Study of 115 Patients with Combined Hepatocellular and Cholangiocarcinoma

Prognostic implications of preoperative, postoperative, and dynamic changes of alpha-fetoprotein and des-gamma (γ)-carboxy prothrombin expression pattern for hepatocellular carcinoma after hepatic resection: a multicenter observational study

Two Pathologic Types of Hepatocellular Carcinoma with Lymph Node Metastasis with Distinct Prognosis on the Basis of CK19 Expression in Tumor.

Analysis of the Risk Factors Influencing the Prognosis of Orthotopic Liver Transplantation for Hepatocellular Carcinoma and Summary of Relevant Clinical Experience

The prognostic significance of clinical and pathological features in hepatocellular carcinoma.

Distinguished Prognosis after Hepatectomy of HBV-related Hepatocellular Carcinoma with or Without Cirrhosis: a Long-Term Follow-Up Analysis

Overexpression of Epcam and CD133 Correlates with Poor Prognosis in Dual-phenotype Hepatocellular Carcinoma

Clinical and Morpho-Molecular Classifiers for Prediction of Hepatocellular Carcinoma Prognosis and Recurrence after Surgical Resection.

CK19 and Glypican 3 Expression Profiling in the Prognostic Indication for Patients with HCC after Surgical Resection

Molecular Markers and Hepatocellular Carcinoma: Lending a Helping Hand in Liver Transplantation?

Prognostic Nomogram for Hepatocellular Carcinoma with Fibrosis of Varying Degrees: a Retrospective Cohort Study.

From Big Data to Diagnosis and Prognosis: Gene Expression Signatures in Liver Hepatocellular Carcinoma

The clinical characteristics and prognostic factors of combined Hepatocellular Carcinoma and Cholangiocarcinoma, Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma after Surgical Resection: A propensity score matching analysis